Biocon gets EIR with VAI status from USFDA for Bengaluru API facility

09 Dec 2024 Evaluate

Biocon has received an Establishment Inspection Report (EIR) with a Voluntary Action Indicated (VAI) status from the U.S. Food and Drug Administration (USFDA), for its API facility (Site 2), located at SEZ Plot no. 2,3,4 and 5 Bommasandra-Jigani Link Road, Bengaluru, Karnataka. This is based on a surveillance inspection conducted by the agency between September 23 to 27, 2024. 

Biocon is India’s largest and Asia’s leading Biotechnology Company with a strategic focus on biopharmaceuticals and research services. It is a fully integrated, innovation driven biopharma enterprise offering affordable solutions for chronic diseases to patient's worldwide.

Biocon Share Price

346.45 1.65 (0.48%)
26-Dec-2024 16:59 View Price Chart
Peers
Company Name CMP
Sun Pharma Inds. 1841.50
Dr. Reddys Lab 1355.15
Cipla 1489.20
Lupin 2181.60
Zydus Lifesciences 959.55
View more..
© 2024 The Alchemists Ark Pvt. Ltd. All rights reserved. MoneyWorks4Me ® is a registered trademark of The Alchemists Ark Pvt. Ltd.